(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) fell by a staggering 27.22% to $6.74 at 10:28 EST on Wednesday, following the last session’s upward trend. NASDAQ is sliding 0.4% to $11,409.22, after three successive sessions in a row of losses. This seems, so far, a somewhat negative trend trading session today.
Novavax’s last close was $9.26, 89.82% below its 52-week high of $91.00.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Sales Growth
Novavax’s sales growth is 72.4% for the ongoing quarter and negative 47.7% for the next.
Previous days news about Novavax (NVAX)
- : Novavax stock sheds a quarter of its value after hours following revenue miss. According to MarketWatch on Tuesday, 28 February, "While our current cash flow forecast for the one-year going concern look-forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration," Novavax said in a…"
More news about Novavax (NVAX).
